Atypical Femoral Fracture Combined with Osteonecrosis of Jaw During Osteoporosis Treatment with Bisphosphonate

Bisphosphonate, a potent anti-resorptive agent, is generally accepted as a safe, effective, well tolerated treatment for postmenopausal osteoporosis. Atypical femoral fracture (AFF) and bisphosphonate related osteonecrosis of jaw (BRONJ) are the increasing morbidities in patients treated with long t...

Descripción completa

Detalles Bibliográficos
Autores principales: Won, Yougun, Lim, Joon-Ryul, Kim, Young-Hwan, Song, Hyung-keun, Yang, Kyu Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society for Bone and Mineral Research 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075270/
https://www.ncbi.nlm.nih.gov/pubmed/25025002
http://dx.doi.org/10.11005/jbm.2014.21.2.155
Descripción
Sumario:Bisphosphonate, a potent anti-resorptive agent, is generally accepted as a safe, effective, well tolerated treatment for postmenopausal osteoporosis. Atypical femoral fracture (AFF) and bisphosphonate related osteonecrosis of jaw (BRONJ) are the increasing morbidities in patients treated with long term bisphosphonate. Pathogenic mechanisms of AFF and BRONJ are not fully identified and not identical. We report a case of BRONJ followed by AFF and its nonunion in a 67-year-old woman patient receiving an oral bisphosphonate during 7 years for the treatment of osteoporosis.

Ejemplares similares